Clinical trials: FEV1
Asthma
Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients
Multinational, multicentre, randomised, double blind, double dummy, placebo and active controlled, 5-way cross over
- Trial name
- NCT00868023
- Testing
- CHF 1535 Next DPI, Foster BDP/Formoterol
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01867762
- Testing
- JNJ 49095397
- Where
- 47 sites in United States, Belgium and 9 more
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01009463
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 188 sites in United States, Argentina and 13 more
- Volunteers
- 1,626 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
Efficacy of Fluticasone/Formoterol in COPD Treatment. The Effect study.
- Trial name
- NCT01946620
- Testing
- Flutiform, Formoterol
- Where
- 15 sites in Bulgaria, Germany and 13 more
- Volunteers
- 1,767 people
- Sponsor
- Mundipharma Research Limited
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Pain
The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)
The investigators propose to assess whether intra-operative intercostal cryoanalgesia using the cryoICE® probe (AtriCure®, Inc., 7555 Innovation Way, Mason, Ohio) provides superior post-operative analgesic efficacy as compared to…
- Trial name
- FROST (NCT02922153)
- Testing
- Cryoanalgesia, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- AtriCure, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Asthma
MGR001 / Advair Diskus Local Equivalence Study in Asthma
The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients
- Trial name
- NCT02245672
- Testing
- MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- Where
- 101 sites in United States
- Volunteers
- 1,128 people
- Sponsor
- Mylan Pharma UK Ltd.
COPD, COPD Exacerbation
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to…
- Trial name
- RETRIEVE (NCT03858348)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma
A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma
This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma
- Trial name
- NCT00785083
- Testing
- FTY720
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis
Asthma
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with…
- Trial name
- NCT01808339
- Testing
- Fluticasone Furoate (FF)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01017952
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 183 sites in United States, Argentina and 13 more
- Volunteers
- 1,635 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00932646
- Testing
- BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Foradil
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
The purpose of this trial is to evaluate the safety and effectiveness of one dose strength of Denufosol compared to placebo in patients with CF and a predicted FEV1 of greater than or equal to 75% but less than or equal to 110%…
- Trial name
- NCT00625612
- Testing
- Denufosol Tetrasodium (INS37217) Inhalation Solution
- Where
- 106 sites in United States, Australia and 2 more
- Volunteers
- 466 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease (COPD)
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
The purpose of the study is to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.
- Trial name
- NCT01555099
- Testing
- AZD5423, Budesonide
- Where
- 44 sites in Bulgaria, France and 6 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Flutiform® Compared With Seretide® in the Treatment of COPD
The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02195375
- Testing
- Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID
- Where
- 5 sites in Australia, China and 3 more
- Volunteers
- 923 people
- Sponsor
- Mundipharma Research Limited
Cystic Fibrosis
Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years
It is hypothesised that inhaled mannitol 400 mg b.d. will lead to a significant improvement in the absolute change in percentage of predicted FEV1 from baseline following eight-weeks of trial treatment compared to treatment with…
- Trial name
- NCT01883531
- Testing
- Inhaled Mannitol
- Where
- United Kingdom
- Volunteers
- 95 people
- Sponsor
- Syntara
Asthma
Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.
The purpose of this study is to assess the effectiveness of JNJ-18054478 measured by the percent change from baseline in Forced Expiratory Volume in one Second (FEV1) after 12 weeks of therapy in patients with persistent asthma.
- Trial name
- NCT00530166
- Testing
- JNJ-18054478
- Where
- 36 sites in United States, Costa Rica and 1 more
- Volunteers
- 26 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.